Kiyota N, Tahara M, Robinson B, Schlumberger M, et al. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 2022 Apr 5. doi: 10.1002/cncr.34181.
PMID: 35380178